'Moderna Of China' Gets $700m Injection As Investors Bet Big On Domestic mRNA Vaccines
Meteoric Rise For Abogen
Executive Summary
Despite a pending domestic approval for BioNTech/Fosun's COVID-19 vaccine, China’s apparent belief in another, domestically developed, mRNA vaccine sees a large group of investors pour hundreds of millions into a little-known private bioventure founded by an ex-Moderna scientist and poised to take on the US biotech.
You may also be interested in...
Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.